Wenzel et al. [30] showed that that assessment of both ex vivo C5b-9 formation and screening for variants in complement genes may categorize patients with malignant hypertension and thrombotic microangiopathy into two different groups, including BP mediated and complement mediated. This evidence concerns the gene C5 and malignant hypertension.